Anorectal administration device

Abstract

The utility model discloses an anorectal drug delivery device which comprises a drug delivery tube and an injection tube connected with the drug delivery tube in an inserted mode, one end of the drug delivery tube is a closed end, a plurality of protruding rings are connected to the tube wall of the drug delivery tube at intervals in the length direction, a drug delivery hole is connected to the tube wall between every two adjacent protruding rings, and an isolation sleeve is arranged in the drug delivery tube. One end of the isolation sleeve is connected with the inner wall of the dosing tube through a connecting part, the other end of the isolation sleeve extends towards the closed end, and the dosing holes are formed between the closed end and the connecting part. By arranging the convex rings, when the dosing tube is inserted into the anorectum, the direct contact between the inner wall of the anorectum and the dosing hole can be reduced as much as possible through the convex rings; meanwhile, the isolation sleeve is arranged, so that the medicine flows through the inner wall of the closed end to be buffered, then flows into the gap between the isolation sleeve and the administration tube and then flows out of the administration hole in the administration process, the medicine pushing-out speed can be effectively reduced, stimulation to the anorectum is reduced, and the discomfort of a patient is further reduced.

Description

Technical Field

[0001] This utility model relates to the field of medical device technology, and in particular to an anorectal drug delivery device. Background Technology

[0002] Anorectal diseases refer to diseases occurring in the anorectal region and some colonic diseases. Currently, there are over seventy types recorded in medical records, with the most common occurrence in the anorectal segment. The patient population for anorectal diseases is currently large. Treatment for anorectal diseases often involves the use of suppositories administered rectally. Suppositories are solid preparations of a specific shape, made from drugs and a suitable matrix, intended for intracavitary administration. Rectal administration refers to the delivery of medication into the intestinal tract through the anus, where it is rapidly absorbed through the rectal mucosa and enters the systemic circulation to exert its therapeutic effect on systemic or local diseases. Clinically, rectal administration is often performed at night before the patient goes to sleep, with the patient wearing a finger cot and inserting the suppository into the anus with their finger. However, this procedure makes it difficult to adjust the insertion depth, potentially leading to the suppository not reaching the designated depth and affecting efficacy. Therefore, existing rectal administration technologies have developed into proctological drug delivery devices. These devices mainly consist of two parts: a delivery tube with a dispensing port for dispensing medication, and a storage device connected to the delivery tube, similar to a syringe, for feeding the medication into the tube. For example, patent document CN202022017976.3 discloses a disposable transrectal drug delivery device, which includes a shell with a drug inlet and a drug outlet, a drug placement chamber disposed inside the shell for drug placement, and a drug delivery push rod connected to the drug placement chamber. Both the drug inlet and the drug outlet are connected to the drug placement chamber, and the diameter of the drug delivery push rod is adapted to the inner diameter of the drug placement chamber. A silicone membrane is provided at the drug outlet of the shell, and a cross-shaped opening is provided on the silicone membrane. Its structure is reliable and easy to use. Through the design of the shell, the drug delivery push rod, and the silicone membrane, it effectively enables convenient, hygienic, efficient, and accurate transrectal drug delivery of various drugs such as ointments and suppositories to reach the target area, thereby reducing drug waste, incomplete drug delivery, and the risk of infection. The unique conical structure of the shell effectively alleviates anal discomfort during transrectal drug delivery.

[0003] However, the above technical solution still has the following shortcomings in actual use: one end of the shell is open, which is not convenient to insert into the anus, and the conical structure of the shell makes the expansion force of the shell on the anus increase continuously when it is gradually inserted into the anus. Moreover, the device does not lubricate the anus during use, which may cause the patient to experience a tearing sensation in the anus. Utility Model Content

[0004] This invention aims to solve at least one of the technical problems existing in the prior art. To this end, this invention proposes a rectal drug delivery device that can reduce patient discomfort.

[0005] According to a first aspect of the present invention, an anorectal drug delivery device includes a drug delivery tube and an injection tube inserted into the drug delivery tube. One end of the drug delivery tube is a closed end. A plurality of convex rings are evenly spaced along the length of the tube wall. A plurality of drug delivery holes are evenly spaced between adjacent convex rings. An isolation sleeve with a gap between it and the closed end is disposed inside the drug delivery tube. The isolation sleeve is coaxially disposed with the drug delivery tube. There is a gap between the outer wall of the isolation sleeve and the wall of the drug delivery tube. One end of the isolation sleeve is connected to the inner wall of the drug delivery tube through a connecting part. The other end of the isolation sleeve extends toward the closed end. Each of the drug delivery holes is disposed between the closed end and the connecting part.

[0006] The rectal drug delivery device according to the present invention has at least the following beneficial effects: by setting convex rings, when the drug delivery tube is inserted into the rectum, several convex rings will minimize the direct contact between the inner wall of the rectum and the drug delivery hole, which can greatly reduce the patient's discomfort; at the same time, by setting an isolation sleeve, the drug flows through the inner wall of the closed end for buffering during the drug delivery process, and then flows into the gap between the isolation sleeve and the drug delivery tube before flowing out from the drug delivery hole. This will effectively reduce the speed at which the drug is pushed out, thereby reducing the stimulation to the rectum and further reducing the patient's discomfort.

[0007] According to some embodiments of the present invention, the drug delivery hole is inclined, and the outlet end of the drug delivery hole is closer to the closed end of the drug delivery tube than the inlet end of the drug delivery hole.

[0008] According to some embodiments of the present invention, the diameter of the isolation sleeve gradually decreases from the closed end away from the administration tube towards the closed end of the administration tube.

[0009] According to some embodiments of this utility model, a wall-breaking cone is also connected to the inner wall of the closed end, and the central axis of the wall-breaking cone coincides with the central axis of the drug delivery tube.

[0010] According to some embodiments of this utility model, the drug delivery tube, the convex ring, the isolation sleeve, and the connecting part are integrally formed, and the drug delivery tube, the isolation sleeve, and the connecting part are all made of silicone material.

[0011] According to some embodiments of the present invention, the injection tube is open at both ends, with one end of the injection tube near the closed end being the push-out end and the other end of the injection tube being the push-in end.

[0012] According to some embodiments of this utility model, the injection tube is sealed and movably connected with a drug-push plate and a push rod with one end fixedly connected to the drug-push plate. The other end of the push rod extends from the push-in end, and the space between the drug-push plate and the push-out end is a drug storage chamber for storing drugs.

[0013] According to some embodiments of the present invention, a positioning plate is connected inside the administration tube, and when the injection tube is inserted into the administration tube, the ejection end is connected to the positioning plate.

[0014] According to some embodiments of the present invention, a one-way limiting member is connected to the inner wall of the drug delivery tube on the side away from the closed end, and the one-way limiting member is connected between the connecting part and the positioning plate.

[0015] According to some embodiments of the present invention, the unidirectional limiting member is a plurality of valves inclined toward the closed end, the minimum encircling size of the plurality of valves in the circumferential direction of the drug delivery tube is smaller than the outer diameter of the push plate, and the maximum encircling size of the plurality of valves in the circumferential direction of the drug delivery tube is larger than the outer diameter of the push plate.

[0016] Additional aspects and advantages of this invention will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention. Attached Figure Description

[0017] The present invention will be further described below with reference to the accompanying drawings and embodiments, wherein:

[0018] Figure 1 This is a schematic diagram of the drug delivery tube of the rectal drug delivery device according to an embodiment of the present invention.

[0019] Figure 2 This is a schematic diagram of the injection tube of the rectal drug delivery device according to an embodiment of the present invention.

[0020] 100. Dosing tube; 110. Closed end; 120. Convex ring; 130. Discharge hole; 131. Outlet end; 132. Inlet end; 140. Isolation sleeve; 150. Connecting part; 160. Wall-breaking cone; 170. Positioning plate; 180. Valve; 200. Injection tube; 210. Push-out end; 220. Push-in end; 310. Push plate; 320. Push rod. Detailed Implementation

[0021] The embodiments of this utility model are described in detail below. Examples of these embodiments are shown in the accompanying drawings, wherein the same or similar reference numerals denote the same or similar elements or elements having the same or similar functions throughout. The embodiments described below with reference to the accompanying drawings are exemplary and are only used to explain this utility model, and should not be construed as limiting this utility model.

[0022] In the description of this utility model, it should be understood that the directional descriptions, such as up, down, front, back, left, right, etc., indicate the directional or positional relationship based on the directional or positional relationship shown in the accompanying drawings. They are only for the convenience of describing this utility model and simplifying the description, and do not indicate or imply that the device or element referred to must have a specific orientation, or be constructed and operated in a specific orientation. Therefore, they should not be construed as limitations on this utility model.

[0023] In the description of this utility model, "several" means one or more, "multiple" means two or more, "greater than," "less than," and "exceeding" are understood to exclude the stated number, while "above," "below," and "within" are understood to include the stated number. If "first" or "second" is used in the description, it is only for the purpose of distinguishing technical features and should not be construed as indicating or implying relative importance, or implicitly indicating the number of indicated technical features, or implicitly indicating the order of the indicated technical features.

[0024] In the description of this utility model, unless otherwise explicitly defined, terms such as "setting," "installation," and "connection" should be interpreted broadly, and those skilled in the art can reasonably determine the specific meaning of the above terms in this utility model in conjunction with the specific content of the technical solution.

[0025] refer to Figure 1 as well as Figure 2 As shown, the rectal drug delivery device according to an embodiment of the present invention includes a drug delivery tube 100 and an injection tube 200 inserted into the drug delivery tube 100. One end of the drug delivery tube 100 is a closed end 110. A plurality of protruding rings 120 are evenly spaced along the length direction on the tube wall of the drug delivery tube 100. A plurality of drug delivery holes are evenly spaced on the tube wall between two adjacent protruding rings 120. An isolation sleeve 140 with a gap between it and the closed end 110 is provided inside the drug delivery tube 100. The isolation sleeve 140 is coaxially arranged with the drug delivery tube 100. There is a gap between the outer wall of the isolation sleeve 140 and the tube wall of the drug delivery tube 100. One end of the isolation sleeve 140 is connected to the inner wall of the drug delivery tube 100 through a connecting part 150. The other end of the isolation sleeve 140 extends toward the closed end 110. Each drug delivery hole is disposed between the closed end 110 and the connecting part 150.

[0026] In actual use, by setting the convex rings 120, when the administration tube 100 is inserted into the rectum, the convex rings 120 will minimize the direct contact between the inner wall of the rectum and the administration hole, which can greatly reduce the patient's discomfort. At the same time, by setting the isolation sleeve 140, the drug flows through the inner wall of the closed end 110 for buffering during administration, and then flows into the gap between the isolation sleeve 140 and the administration tube 100 before flowing out from the administration hole. This will effectively reduce the speed of drug expulsion, thereby reducing the stimulation to the rectum and further reducing the patient's discomfort.

[0027] Specifically, medications can be classified as suppositories and ointments, and should be used according to the actual situation.

[0028] In some specific embodiments of this utility model, it may also have the following additional technical features: the injection tube 200 is open at both ends, the end of the injection tube 200 near the closed end 110 is the push-out end 210, and the other end of the injection tube 200 is the push-in end 220.

[0029] In some specific embodiments of this utility model, it may also have the following additional technical features: a push plate 310 and a push rod 320 with one end fixedly connected to the push plate 310 are sealed inside the injection tube 200. The other end of the push rod 320 extends out from the push-in end 220. The area between the push plate 310 and the push-out end 210 is a drug storage chamber for storing drugs.

[0030] In some specific embodiments of this utility model, it may also have the following additional technical features: a positioning plate 170 is connected inside the administration tube 100, and when the injection tube 200 is inserted into the administration tube 100, the push-out end 210 is connected to the positioning plate 170.

[0031] In some specific embodiments of this utility model, it may also have the following additional technical features: the administration port is inclined, and the outlet end 131 of the administration port is closer to the closed end 110 of the administration tube 100 than the inlet end 132 of the administration port. Through the above design, the flow direction of the drug in the administration port is cleverly reversed with the flow direction in the gap between the isolation sleeve 140 and the administration tube 100. Compared to the traditional drug flow method, where the flow direction of the drug in the administration port is consistent with the flow direction in the gap between the isolation sleeve 140 and the administration tube 100, resulting in direct outflow, this embodiment significantly slows down the rate at which the drug flows out of the administration port, thereby effectively reducing patient discomfort during medication administration.

[0032] In some specific embodiments of this utility model, it may also have the following additional technical features: the diameter of the isolation sleeve 140 gradually decreases from the closed end 110 away from the administration tube 100 towards the closed end 110 of the administration tube 100. The direction from the closed end 110 away from the administration tube 100 towards the closed end 110 of the administration tube 100 is the administration direction, and also the direction of movement of the push plate 310 during administration. Through the above-mentioned refined structural optimization, clear indication and flow regulation functions are achieved during use. Specifically, as the push plate 310 gradually contacts the connecting part 150 and subsequently continues to contact the isolation sleeve 140, the design cleverly introduces a significant tactile feedback. This change in feel not only provides clear feedback to the user but also indicates the direction for optimizing the operating procedure for medical personnel and manufacturers. More importantly, during drug administration, if rapid squeezing within a short period causes medication to accumulate in the isolation sleeve 140 and fail to flow into the predetermined gap in time, the pressure generated by the medication will cause the diameter of the isolation sleeve 140 to slightly expand, thereby reducing the gap between it and the inner wall of the administration tube 100. This mechanism effectively controls the outflow rate of the medication, preventing patient discomfort due to over-injection. As the squeezing action is released, the medication in the isolation sleeve 140 gradually begins to be released through the administration port, and the isolation sleeve 140 returns to its initial position, restoring the gap between it and the administration tube 100. This process not only achieves automatic flow regulation but also provides the user with intuitive tactile feedback. The user can clearly feel the change in resistance, prompting them to adjust the speed of pushing the medication, ensuring the accuracy and safety of drug administration.

[0033] In some specific embodiments of this utility model, it may also have the following additional technical features: a wall-breaking cone 160 is connected to the inner wall of the closed end 110, and the central axis of the wall-breaking cone 160 coincides with the central axis of the administration tube 100. Specifically, by setting the wall-breaking cone 160, the protective shell of the drug can be broken, allowing the active ingredient in the drug to flow out from the protective shell and through the administration hole to the patient's affected area to complete the administration. This makes the range of drug selection wider, allowing for the selection of capsule drugs that are difficult to store and require a sealed protective shell, or ordinary drugs that can be stored for a long time under normal conditions.

[0034] In some specific embodiments of this utility model, it may also have the following additional technical features: the administration tube 100, the convex ring 120, the isolation sleeve 140 and the connecting part 150 are integrally formed, and the administration tube 100, the isolation sleeve 140 and the connecting part 150 are all made of silicone material.

[0035] In some specific embodiments of this utility model, it may also have the following additional technical features: a one-way limiting member is connected to the inner wall of the administration tube 100 on the side away from the closed end 110, and the one-way limiting member is connected between the connecting part 150 and the positioning plate 170.

[0036] In some specific embodiments of this utility model, it may also have the following additional technical features: the unidirectional limiting member is a plurality of valves 180 inclined toward the closed end 110, the minimum encircling size of the plurality of valves 180 in the circumferential direction of the administration tube 100 is smaller than the outer diameter of the push plate 310, and the maximum encircling size of the plurality of valves 180 in the circumferential direction of the administration tube 100 is larger than the outer diameter of the push plate 310.

[0037] Specifically, the multiple valves 180 can be inclined triangular or elliptical structures, thus forming a structure similar to a hollow cone with one side larger than the other when closed. In this way, after the injection tube 200 abuts against the positioning plate 170, the push rod 320 continues to push the drug delivery plate 310 in the drug delivery direction, gradually passing through each valve 180. At this time, since the valves 180 are inclined towards the closed end 110, they do not hinder the movement of the drug delivery plate 310. However, when the drug delivery plate 310 wants to retract after completely passing through each valve 180, the structure of the valves 180 forms resistance to prevent the drug delivery plate 310 from retracting, thus making the entire mechanism move only in one direction, thereby avoiding the risk of being used multiple times.

[0038] The embodiments of the present utility model have been described in detail above with reference to the accompanying drawings. However, the present utility model is not limited to the above embodiments. Within the scope of knowledge possessed by those skilled in the art, various changes can be made without departing from the spirit of the present utility model.

Claims

1. A rectal drug delivery device, comprising a drug delivery tube (100) and an injection tube (200) inserted into the drug delivery tube (100), characterized in that, One end of the administration tube (100) is a closed end (110). Multiple protruding rings (120) are evenly spaced along the length of the tube wall of the administration tube (100). Multiple administration holes are evenly spaced between adjacent protruding rings (120). An isolation sleeve (140) with a gap between it and the closed end (110) is provided inside the administration tube (100). The isolation sleeve (140) is coaxially arranged with the administration tube (100). There is a gap between the outer wall of the isolation sleeve (140) and the tube wall of the administration tube (100). One end of the isolation sleeve (140) is connected to the inner wall of the administration tube (100) through a connecting part (150). The other end of the isolation sleeve (140) extends toward the closed end (110). Each administration hole is located between the closed end (110) and the connecting part (150).

2. The rectal drug delivery device according to claim 1, characterized in that, The administration port is inclined, and the outlet end (131) of the administration port is closer to the closed end (110) of the administration tube (100) than the inlet end (132) of the administration port.

3. The rectal drug delivery device according to claim 1, characterized in that, The diameter of the isolation sleeve (140) gradually decreases from the closed end (110) away from the administration tube (100) toward the closed end (110) of the administration tube (100).

4. The rectal drug delivery device according to claim 1, characterized in that, A wall-breaking cone (160) is also connected to the inner wall of the closed end (110), and the central axis of the wall-breaking cone (160) coincides with the central axis of the drug delivery tube (100).

5. The rectal drug delivery device according to claim 1, characterized in that, The drug delivery tube (100), the convex ring (120), the isolation sleeve (140), and the connecting part (150) are integrally formed, and the drug delivery tube (100), the isolation sleeve (140), and the connecting part (150) are all made of silicone.

6. The rectal drug delivery device according to claim 1, characterized in that, The injection tube (200) is open at both ends. The end of the injection tube (200) near the closed end (110) is the push-out end (210), and the other end of the injection tube (200) is the push-in end (220).

7. The rectal drug delivery device according to claim 6, characterized in that, The injection tube (200) is sealed and movably connected to a push plate (310) and a push rod (320) with one end fixedly connected to the push plate (310). The other end of the push rod (320) extends out from the push-in end (220). The area between the push plate (310) and the push-out end (210) is a drug storage chamber for storing drugs.

8. The rectal drug delivery device according to claim 7, characterized in that, The administration tube (100) is connected to a positioning plate (170). When the injection tube (200) is inserted into the administration tube (100), the ejection end (210) is connected to the positioning plate (170).

9. The rectal drug delivery device according to claim 8, characterized in that, A one-way limiting member is connected to the inner wall of the administration tube (100) on the side away from the closed end (110), and the one-way limiting member is connected between the connecting part (150) and the positioning plate (170).

10. The rectal drug delivery device according to claim 9, characterized in that, The unidirectional limiting component consists of multiple valves (180) inclined toward the closed end (110). The minimum circumferential size of the multiple valves (180) in the administration tube (100) is smaller than the outer diameter of the push plate (310), and the maximum circumferential size of the multiple valves (180) in the administration tube (100) is larger than the outer diameter of the push plate (310).

Images